Abstract 454P
Background
Deep Vein Thrombosis and Pulmonary Embolism have been associated with significant morbidity and mortality worldwide. The risk of developing lower limb Deep Vein Thrombosis may be associated with cancer-related, patient, and treatment-related risk factors. Although the association between cancer and venous thromboembolism is well known, there is a paucity of information in Asian patients with respect to cancer-associated thrombosis.
Methods
This prospective, observational study was conducted at Artemis Hospital, Gurugram, a Tertiary Health Care Center in (Northern) India. We identified all the consecutive patients with histologically confirmed newly diagnosed Stage III/IV solid tissue malignancies between June 2021 and May 2022. Duplex Doppler Ultrasound of the bilateral lower limb was performed to determine the prevalence of Deep Vein Thrombosis. Data on clinical and tumor characteristics were collected and compared among patients with and without lower limb Deep Vein Thrombosis.
Results
A total of 100 patients were enrolled in the study. On Duplex Doppler venous ultrasound, the prevalence of lower limb deep vein thrombosis was 14%. An adjusted multivariable regression analysis showed that advanced stage (p=0.008), leukocytosis(p=0.042), OR[1.0],95% CI(1.00,1.2), deranged coagulation profile (Raised APTT, PT)(p=0.01),OR [1.74], 95%CI(1.14,2.679) hypercholesterolemia(p=0.007), OR[1.02], 95%CI (1.004,1.05) were independent predictors of Deep vein Thrombosis. The highest prevalence of venous thromboembolism was for pancreatic (2%) and lung cancer (2%).
Conclusions
Cancer-related thrombosis has to bear in treatment outcomes as well as morbidity and mortality. Routine lower-extremity Venous Doppler Ultrasonographic screening is useful for early detection and management at an initial evaluation of stage III/IV solid malignancies. There is a paucity of data on Indian patients. This is the first study conducted in the Indian subcontinent that has identified high-risk factors and prevalence of venous thromboembolism. Such study design will help us in formulating national-level guidelines for prophylaxis of cancer-associated thrombosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
462P - Limited duration of treatment with checkpoint inhibitors in complete responders, yet prolonged survival: A real-world study from India
Presenter: Nitin Murthy
Session: Poster viewing 06
463P - Cost effectiveness of palbociclib and ribociclib in metastatic breast cancer in India using ICER and QALY
Presenter: Krishnamani Kalpathi
Session: Poster viewing 06
464TiP - Phase III study of adjuvant encorafenib plus binimetinib vs placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design
Presenter: Alexander van Akkooi
Session: Poster viewing 06
465TiP - Evaluation of quality of life and functional outcomes following limb salvage surgery in extremities sarcomas
Presenter: naveen kushwaha
Session: Poster viewing 06
YO2 - A case of locally advanced breast cancer with biomarker conversion successfully treated with neoadjuvant chemotherapy-immunotherapy combination
Presenter: Long Nguyen
Session: Poster viewing 06
YO3 - Metastatic Breast cancer to esophagus: A case report and review of literature
Presenter: Bhuvana J
Session: Poster viewing 06
YO4 - Succinate Dehydrogenase deficient GISTs is a diagnostic and therapeutic dilemma? : A case report.
Presenter: Nurazzahra Kamarudin
Session: Poster viewing 06
YO5 - Complete Radiologic and Pathologic Response in a Metastatic Gallbladder Adenocarcinoma Patient treated with Checkpoint Inhibitor/Chemotherapy Combination: A Case Report
Presenter: Tisha Gay Tancongco
Session: Poster viewing 06
YO7 - Orbital Metastasis in Prostrate Cancer: A Case Report
Presenter: Shabnam Rehman
Session: Poster viewing 06
YO10 - BRCA2 Mutated Recurrent Adult Granulosa Cell Tumor Treated with PARP Inhibitor
Presenter: Debapriya Mondal
Session: Poster viewing 06